Xenetic Biosciences (NASDAQ:XBIO) Stock Crosses Above 50-Day Moving Average – Time to Sell?

Xenetic Biosciences, Inc. (NASDAQ:XBIO) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.88 and traded as high as $3.28. Xenetic Biosciences shares last traded at $3.28, with a volume of 6,690 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Xenetic Biosciences Trading Down 0.3%

The company’s fifty day moving average is $2.88 and its two-hundred day moving average is $2.84. The stock has a market cap of $7.51 million, a price-to-earnings ratio of -2.83 and a beta of 2.10.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter. The firm had revenue of $0.66 million during the quarter. Xenetic Biosciences had a negative net margin of 75.90% and a negative return on equity of 40.62%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC acquired a new stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned 0.60% of Xenetic Biosciences as of its most recent filing with the Securities and Exchange Commission. 15.12% of the stock is owned by institutional investors and hedge funds.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.